Association des Métiers Médicaux des Industriels de Santé

History of the AMMIS

AMMIS (previously called AMIPS) is medical and scientific organization re-founded in 2018. It is a not-for-profit association and exists solely for the benefit of its members. Currently AMMIS has approximately 100 members.

Who are AMMIS members?

AMMIS is open to anyone who, through their expertise, contribute to the development of innovative preventive and therapeutic methods and to the spreading of high quality information on these treatments (pharmaceutical company, CRO, recruitment agencies, industrial property experts).

Aims of the AMMIS:

– To help its members maintain a high level of expertise in disciplines, both traditional and innovative, which is broadly defined as “Pharmaceutical Medicine”. 

– To facilitate the professional life of members by making available to them:

  • job exchanges
  • different networking opportunities
  • access to quality training
  • access to a group of experts in Pharmaceutical Medicine

– To help its members uphold ethical rules and professional conduct within the Pharmaceutical Industries.

– To demonstrate the added value of physicians and scientists working in the pharmaceutical industries to medical, scientific, legal, governmental and ordinal authorities.

AMMIS committee :

Chairperson : Dr Francois-Xavier Frapaise

Vice Chairperson : Dr Anne-Marie Masquelier

Treasurer: Dr Christine Roy

Secretary: Dr Julien Gautry

Dr Veronique Dugue

Dr Irina Leurs

Dr Thierry Maruet

Dr Vanessa Legué

Dr Emmanuelle Voisi

Dr Anna Rodet

AMMIS events :

AMMIS organizes meetings and panel discussions on the main emerging themes relevant to our pharmaceutical industry.

Our first (very well attended) meeting early 2019 addressed and discussed the following topic: “2019, the health industry is changing, and us? This event was focused on a changing health industry’s environment and brought together 80 representatives from different medical professions in the pharmaceutical industry.

For our next meeting we have chosen a subject that is a great concern for both authorities and industry, namely “Real World Evidence” (RWE); What does RWE really mean? How to best collect and analyze data ? What are the expectations of the authorities and the pharmaceutical industry regarding this data?

This next AMMIS meeting will take place on:

Tuesday, June 11 from 6:20 pm to 8:30 pm

(64 Avenue Pierre Grenier, 92100 Boulogne-Billancourt)

« RWE – Are we (RWE) ready? »

6:20 pm  – Welcome of participants

6:40 pm  – Opening by Xavier FRAPAISE – President of AMMIS

6:45 pm – Fifty Shades of RWE Mathieu ROBAIN, UNICANCER

7:00 pm  RWE: What are the objectives? What are the expectations?

  • Health Authorities Perspective –Mahmoud ZUREIK, Epi-Phare (ANSM / CNAM)
  • Pharmaceutical Industry Perspective – Juliette LONGIN, MERCK and Jean Marc PINGUET, ROCHE

Questions / Discussion with the audience

8:00 pm – Can one or more types of scientifically relevant studies be defined that satisfy the main stakeholders?

  • Round table moderated by Mathieu ROBAIN with participation of all the speakers

Questions / Discussion with the audience

8:30 pm  –  Closing cocktail

To contact AMMIS

Email :

Address : 10 rue de Remusat 75016 Paris

Website :